IP Library Granted Patent US 9,839,669
Granted Patent B2
US 9,839,669 · App. 15/064,285 · Granted Dec 12, 2017

Antiviral agent comprising recombinant mistletoe lectins

Inventors: Hans Lentzen (Rosrath, DE); Klaus Witthohn (Overath, DE)
Assignee: Cytavis Biopharma GmbH
A61K38/168A61K45/06C07K14/42
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,839,669
App. No.
15/064,285
Granted
Dec 12, 2017
Kind
B2
Abstract

An antiviral agent containing recombinant mistletoe lectins for treating virus infections and a medicament and/or pharmaceutical composition for treating virus infections are described. Recombinant mistletoe lectin polypeptides can be a mistletoe lectin A-chain, as well as parts or fragments of the mistletoe lectin A-chain. The antiviral agent can be used for any number of virus infections, such as Herpes simplex, adenovirus, poliovirus, and poxvirus. Also, the antiviral agent can be used for skin virus warts, anogenital warts, mucous membrane warts and malignant tumors such as cervical cancer, penis and vulvar cancer.

Claims (8)

1. A method of treating a viral infection comprising administering to a patient with a viral infection a drug containing a recombinant mistletoe lectin, wherein the recombinant mistletoe lectin is a mistletoe lectin A-chain selected from the group consisting of the amino acid sequences of SEQ ID NO: 1-3, or comprises parts and fragments thereof, or is a combination thereof, and wherein the viral infection comprises Herpes simplex virus infection.

2. The method of claim 1 , wherein a cytotoxicity of recombinant mistletoe lectin is less than 0.5 ng/plaque.

3. The method of claim 1 , wherein the drug further comprises a pharmaceutically acceptable carrier.

4. The method of claim 1 , wherein the drug further comprises interleukins, interferons, a cytostatic agent.

5. The method according to claim 1 , wherein the recombinant mistletoe lectin further comprises a mistletoe lectin B-chain selected from the group consisting of amino acid sequences of SEQ ID NOs: 4-12, or comprises parts and fragments thereof, or is a combination thereof.

6. The method according to claim 1 , wherein the recombinant mistletoe lectin further comprises a mistletoe lectin A-chain of amino acid sequence of SEQ ID NO: 1 and further comprises the mistletoe lectin B-chain of amino acid sequence SEQ ID NO: 4.

7. A method of reducing a recurrence of a viral infection comprising administering to a patient with a viral infection a drug containing a recombinant mistletoe lectin, wherein the recombinant mistletoe lectin is a mistletoe lectin A-chain selected from the group consisting of the amino acid sequences of SEQ ID NOs: 1-3, or comprises parts and fragments thereof, or is a combination thereof, wherein the viral infection comprises Herpes simplex virus infection.

8. The method according to claim 7 , wherein the recombinant mistletoe lectin further comprises a mistletoe lectin B-chain selected from the group consisting of amino acid sequences of SEQ ID NOs: 4-12, or comprises parts and fragments thereof, or is a combination thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: CYTAVIS BIOPHARMA GMBH
To: MELEMA PHARMA GMBH
Reel/Frame 044378/0451 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2016
From: LENTZEN, HANS; WITTHOHN, KLAUS
To: CYTAVIS BIOPHARMA GMBH
Reel/Frame 037924/0717 →
Priority Claims (1)
DE 10 2011 003 478 · Feb 1, 2011 · national
Continuity (2)
Continuation 13983101
Related Publication 20160175390A1 · Jun 23, 2016